A K_Ca 2.2/2.3 Opener Reverses ET-1-Induced NLRP3 Activation in Hypertensive Mice Corpora Cavernosa

Abstract

Hypertension-induced erectile dysfunction is associated with endothelial dysfunction in the corpus cavernosum. Membrane depolarization activates the NLRP3 inflammasome, with downregulation of endothelial Ca²⁺-activated K⁺ channels type 2.3 (K_Ca 2.3) and upregulation of endothelin-1 (ET-1) linked to erectile dysfunction. However, underlying mechanisms remain incompletely understood. We hypothesized that activating K_Ca 2.2/2.3 channels reverses erectile dysfunction and ET-1-induced NLRP3 activation in hypertensive DOCA/salt mice. Hypertension was induced in mice using a DOCA/salt model, with unilaterally nephrectomized mice as controls. We measured blood pressure, intracavernous pressure (ICP), and corpus cavernosum (CC) contractility, and performed immunoblots for K_Ca 2.3, caspase-1, and interleukin-1β (IL-1β). DOCA/salt mice showed impaired erectile function and increased IL-1β activity and reduced K_Ca 2.3 expression. Treatment with the endothelin receptor antagonist bosentan or the K_Ca 2.2/2.3 channel opener NS13001 reversed these dysfunctions and reduced ET-1-induced NLRP3 activation. NS13001 also restored decreased currents in endothelial cells exposed to ET-1. These findings establish that hypertension-induced erectile dysfunction involves an ET-1/membrane depolarization/NLRP3 inflammasome axis in corpus cavernosum endothelial cells, and that targeting endothelial K_Ca 2.2/2.3 channels represents a promising therapeutic strategy to counteract erectile dysfunction.

1. Introduction

Erectile dysfunction (ED) commonly accompanies arterial hypertension and reflects systemic endothelial dysfunction. Penile erection is mediated by endothelium-dependent vasodilation within the corpus cavernosum (CC), which enhances cavernosal blood inflow and increases sinusoidal compliance [1,2,3,4,5]. A key endothelial mechanism underlying this response is membrane hyperpolarization mediated by small-conductance Ca²⁺-activated K⁺ channels (K_Ca 2.x), which amplifies Ca²⁺ entry, sustains endothelial nitric oxide synthase (eNOS) activity, and promotes the release of vasodilators that relax cavernosal smooth muscle [6,7,8]. The K_Ca is a diverse group of potassium channels which are divided into small SK_Ca (K_Ca 2.1, K_Ca 2.2, and, K_Ca 2.3), intermediate (IK_Ca or (K_Ca 3.1), and large conductance Ca²⁺-activated K⁺ channels (BK_Ca or K_Ca 1.1) [9].

ED is a predictor of cardiovascular disease, stroke, and perhaps all-cause mortality—through an augmentation in cardiovascular mortality and independently of traditional risk factors [10,11]. The K_Ca 2.3 channel is essential for nitric oxide (NO) signaling through endothelial NO synthase (eNOS) activation. NO produced by eNOS in the vascular bed not only mediates vasodilatation but also has anti-inflammatory functions [12,13]. The downregulation of K_Ca 2.3 leads to endothelial dysfunction and ED, and expression and/or function of K_Ca 2.3 channels are reduced in arterial hypertension [6,14].

The activation of K_Ca 2.3 reduces blood pressure [3] and improves erectile function in rats. Furthermore, K_Ca 2.3 has an anti-inflammatory effect, mainly by inhibiting the release of proinflammatory cytokines such as interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-α) and by inhibiting the migration of immune cells. Thus, K_Ca 2.3 channel plays an essential role in the modulation of the immune system [12,13].

ET-1 is closely linked with endothelial dysfunction, mainly by the modulation of various populations of K⁺ channels, such as inward-rectifying (K_ir), ATP-sensitive (K_ATP), voltage-gated (K_v), and K_Ca channels [6,15]. ET-1 has been shown to activate mononuclear phagocytes and to promote the release of TNF-α, IL-1β, and IL-6, thereby increasing the interaction between endothelial cells and monocytes. Moreover, a recent study showed that ET-1 activates NLRP3 via Ca²⁺-induced ROS generation and impairs erectile function [16,17,18].

Membrane depolarization is thought to be involved in the activation of NLRP3 [19]. Therefore, the present study hypothesized that opening K_Ca 2.3 channels prevents the activation of NLRP3 and reverses ED. To address the hypothesis, studies were conducted on the effect of ET-1 and an opener of KCa 2.2/2.3 channels, NS13001, on the endothelial cell K⁺ currents, and the effect of NS13001 on erectile function was examined in a DOCA/salt hypertensive mouse model.

Based on these results, this study provides a novel insight into the role of K_Ca 2.3 channels in mediating the relationship between hypertension and ED, conditions that often co-exist. The therapeutic potential of the K_Ca 2.3/K_Ca 2.2 channel opener NS13001 in reversing these effects is a key finding, offering a targeted approach to treat ED and hypertension. This timely research highlights potassium channels as promising therapeutic targets for inflammation-related vascular diseases and ED.

2. Materials and Methods

2.1. Animals

Male mice 10–12 weeks-old C57BL/6 (~25 g) were housed in a room with controlled temperature (20–22 °C) and on light/dark cycles of 12 h with free access to standard chow with 0.2% sodium (Altromin 1324, Brogaarden, Denmark) and filtered water. All experimental protocols adhered to the ARRIVE guidelines [20], followed Danish legislation of animal use for scientific procedures as described in the ‘Animal Testing Act’ (Consolidation Act No. 726 of 9 September 1993 as amended by Act No. 1081 of 20 December 1995) and were approved by the Danish Animal Experiments Inspectorate (permission 2019-15-0201-00009).

2.2. DOCA-Salt Hypertension and Arterial Blood Pressure Measurements

Deoxycorticosterone acetate (DOCA) -salt hypertension was induced as previously described [21]. Mice were anesthetized using isoflurane (5% for induction and 2% for maintenance) in 100% oxygen (2 L/min). Briefly, mice were unilaterally nephrectomized and deoxycorticosterone-acetate (DOCA; 1 g/kg) silastic pellets were implanted subcutaneously in the scapular region. After the DOCA surgery, the mice received buprenorphine (0.05 mg/kg every 8 h for 24 h). DOCA mice received water containing 1% NaCl and 0.2% KCl, for 3 weeks. Unilaterally nephrectomized (UNI) control mice received silastic pellets without DOCA and tap water. Animals received either the non-selective ET-1 antagonist bosentan [30 mg/day/kg (diluted in saline) of body weight, per gavage], NS13001 [1 mg/day/kg diluted in polyethylene glycol) of body weight, per gavage], apamin [1 mg/day/kg (diluted in saline) of body weight, subcutaneous], or its respective vehicle for 11 days starting 10 days after the surgery. Systolic blood pressure (SBP) was measured in mice with a tail-cuff method using a RTBP1001 blood pressure system (Kent Scientific Corporation, 1116 Litchfield St, Torrington, CT, USA).

2.3. Isolation of Corpus Cavernosum (CC) Strips and CC Primary Endothelial Cells

For isolation of primary endothelial cells and corpus cavernosum (CC) strips, the mouse was gently placed in a transparent chamber (19 cm wide × 29 cm deep × 13 cm high) and exposed to isoflurane 3% in 100% oxygen (2 L/min). Once the pain reflexes disappeared, the animals were decapitated. After this procedure, the CC was isolated and split into 2 strips, one was used for CC contractility measurements, and the other for immunoblotting.

2.4. Drugs and Solutions

Physiological Krebs–Henseleit buffer of the following composition was used: NaCl 130 mM, KCl 4.7 mM, KH₂PO₄ 1.18 mM, MgSO₄·7H₂O 1.17 mM, NaHCO₃ 14.9 mM, EDTA 0.026 mM, CaCl₂·2H₂O 1.6 mM and D-glucose 5.55 mM. A high concentration of KCl buffer of the following composition was used: NaCl 14 mM, KCl 120 mM, KH₂PO₄ 1.18 mM, MgSO₄·7H₂O 1.17 mM, NaHCO₃ 14.9 mM, EDTA 0.026 mM, CaCl₂·2H₂O 1.6 mM and D-glucose 5.55 mM. pH in all buffers was adjusted to 7.35 before its use. The incubations were performed with ET-1 (100 nM, Tocris 1160; diluted in 5% BSA + 95% deionized water), MCC950 (1 µM, Cayman Chemical 17510; diluted in 5% DMSO and 95% deionized water), NS13001 (100 nM, ChemShuttle, CA, USA; diluted in polyethylene glycol), apamin (100 nM, Latoxan L8407; diluted in deionized water). The in vivo experiments were performed with bosentan (30 mg/day/kg, Sigma Aldrich 157212-55-0; diluted in saline), NS13001 (1 mg/day/kg, ChemShuttle, CA, USA; diluted in polyethylene glycol), apamin (1 mg/day/kg; Latoxan L8407; diluted in saline).

2.5. Culture of Primary Endothelial Cells of Corpus Cavernosum

Endothelial cells from CC of intact C57BL/6 mice were isolated as previously described [3]. Briefly, a freshly isolated CC strip was placed in sterile PBS and cut into small pieces together with collagenase II (400 mg mL⁻¹, Worthington Biochemical Corporation, Lakewood, NJ, USA) for 60 min at 37 °C. The sampled tissue was centrifuged at 900 RPM with isolation of the pellet and transferred to a coated gelatin and collagen Petri dish at 37 °C. The culture media was Dulbecco’s Modified Eagle Medium with 1% Fungizone, 1% penicillin streptomycin, newborn fetal calf serum and HEPES. When they reached confluence after 1–4 days, the cells were incubated with the endothelium-specific CD102 [intracellular adhesion molecule 2 (ICAM2)] rat anti-mouse (diluted 1:500, BD Biosciences 553326. RRID: AB_394784) for 30 min followed by incubation with Dynabeads with sheep anti-rat IgG (Life Technologies, Oslo, Norway) for 30 min at 4 °C. Trypsin was added to separate the cells from the Petri dish and transferred to dynamag 5TM (Life Technologies, Oslo, Norway) for 2 min cleaning. The pellet was dissolved and left in a coated Petri dish for further cultivation in endothelial cell growth serum (Provitro AG, Berlin, Germany). The endothelial cells were treated with ET-1 (4 h) in the presence of NS13001 (30 min), apamin (30 min), or vehicle. After the treatment, the cells were separated for patch-clamp or Western blot experiments.

2.6. Patch-Clamp Electrophysiology

Endothelial cells were detached from the Petri dish with trypsin-EDTA, washed, and patch clamped using a Port-a-Patch automated system (Nanion Technologies, Munich Germany), as previously described [3]. Briefly, 3–5 MΩ resistance microchips were used. Currents were recorded using an extracellular solution containing (in mM): 140 NaCl, 4 KCl, 10 Glucose, 10 HEPES, 2 CaCl₂ and 1 MgCl₂, pH 7.3–7.4. The intracellular solution was prepared as described previously [22] and contained (in mM): 30 KCl, 100 K-Aspartate, 1 mM MgCl₂, 10 mM EGTA, 3 Na₂ATP, 5 mM HEPES, and 8.5 CaCl₂, pH 7.2. The osmolarity of all solutions was 290–320 mOsm. All voltages were corrected for calculated junction potentials present between the internal and external solutions before seal formation. The K⁺ currents were activated by voltage steps from −140 to 140 mV in 40 mV increments for 250 ms and using a holding membrane potential of −80 mV. Currents measured at a step of 100 mV were used to compare the effects of the K_Ca 2.2/2.3 openers or blockers used in this study. All current amplitudes were expressed as current density (pA/pF) normalized to cell capacitance.

2.7. In Vivo Measurements of Intracavernosal Pressure and Mean Arterial Pressure

Mice were anesthetized with 2% isoflurane for induction and maintained with 1.5% in 100% oxygen (2 L/min) [4]. Then, the left carotid artery and right CC of each mouse were cannulated for continuous monitoring of mean arterial pressure (MAP) and intracavernosal pressure (ICP), respectively.

In the DOCA and UNI mice treated with either vehicle, bosentan, NS13001, or apamin, the cavernosal nerve was electrically stimulated with silver electrodes at different frequencies (5 V, 1 ms pulses, and frequencies between 0.5 and 20 Hz for 60 s stimulations) to induce changes in ICP. Each frequency was followed by a 2 min resting period. The cavernosal nerve mediates the relaxation and contraction of the cavernous smooth muscle, together regulating the erectile function of penile tissue [23].

In intact C57BL/6 mice, the cavernosal nerve was stimulated electrically with silver electrodes at 6 V, 1 ms pulse width, for 60 s, and the frequency at 16 Hz to induce changes in ICP and obtain the maximum (max) ICP/MAP. Subsequently, the cavernosal nerve was stimulated at the same parameters and varying the frequency from 2 to 8 Hz to determine the 50% (submaximal) of ICP/MAP for each mouse [24]. Then, we administered intracavernosal NS13001 (0.1 µg/kg), apamin (20.27 µg/kg), or vehicle. A new submaximal stimulation was performed at 3, 10, 20, and 30 min, and the maximal stimulation at 25 min. A second intracavernosal administration with ET-1 (0.2492 µg/kg) or vehicle was performed, and the submaximal stimulation was performed at 3, 10, 20, and 30 min, and the maximal stimulation at 25 min.

2.8. Cavernosal Tissue Contractility

Cavernosal strips from intact C57BL/6 mice were isolated and mounted in 10 mL-myograph chambers (Danish Myo Technology, Aarhus, Denmark) containing buffer continuously bubbled with a mixture of BioAir (5% CO₂ and 19.82% O₂ in nitrogen) and maintained at 37 °C as previously described [2]. The tissues were stretched to a resting force of 2.5 mN and allowed to equilibrate for 60 min. Changes in isometric force were recorded using the PowerLab/8SP data acquisition system (Chart software, version 7; ADInstruments, Colorado Springs, CO). At the end of the equilibration period, phenylephrine (1 μM) was added to the organ bath to verify the preparations’ contractile ability.

The contraction was evaluated by cumulative concentration-response curves to phenylephrine (1 nM to 100 µM) in CC strips. Relaxation was evaluated by constructing cumulative concentration-response curves for acetylcholine (ACh) (100 pM–3 µM; endothelium-dependent relaxation) and sodium nitroprusside (SNP) (10 pM–100 µM; NO donor) in CC strips pre-contracted with phenylephrine (10 µM). To investigate neurogenic relaxations in CC strips, the preparations were treated with guanethidine (30 µM) and atropine (1 µM) as previously described [25]. Then, the preparations were contracted with phenylephrine, and electrical field stimulation (0.5 to 32.0 Hz) was performed.

2.9. Immunoblotting

DOCA or UNI animals received either the non-selective ET-1 antagonist bosentan [30 mg/day/kg (diluted in saline) of body weight, per gavage], NLRP3 inhibitor [10 mg/day/kg (diluted in saline) of body weight, subcutaneous], NS13001 [1 mg/day/kg diluted in polyethylene glycol of body weight, per gavage], apamin [1 mg/day/kg diluted in saline of body weight, subcutaneous], or its respective vehicle for 11 days starting 10 days after the surgery. The samples for this immunoblotting experiments were obtained from mice exclusively used for immunoblotting, thereby avoiding interference from in vivo or ex vivo stimulation.

The CC endothelial cells were obtained from healthy mice and treated with ET-1 (100 nM, Tocris 1160; diluted in 5% BSA + 95% deionized water), MCC950 (1 µM, Cayman Chemical 17510; diluted in 5% DMSO and 95% deionized water), NS13001 (100 nM, ChemShuttle, CA, USA; diluted in polyethylene glycol), apamin (100 nM, Latoxan L8407; diluted in deionized water).

The isolated CC from intact C57BL/6 mice were cleaned from surrounding fat tissue and then snap-frozen in liquid nitrogen for storage at −80 °C. The samples were later homogenized in a lysis buffer [50 mM Tris/HCl, 150 mM NaCl, 1% Nonidet P40, 1 mM EDTA, 1 μg/mL leupeptin, 1 μg/mL pepstatin, 1 μg/mL aprotinin, 1 mM sodium orthovanadate, 1 mM phenylmethanesulfonyl fluoride (PMSF), and 1 mM sodium fluoride] [4]. Protein concentration was determined by the Lowry assay. Spectra multicolor broad range protein ladder (10 to 260 KDa) was used as protein standard. Aliquots with 60 µg of proteins were prepared and separated by electrophoresis at 100 V for 2 h at 4° C in 4–20% Criterion TGX Stain-Free gels (bio rad) and transferred for 1 h to a nitrocellulose membrane at 100 V at 4° C. After transfer, total protein was visualized using stain-free technology by exposing the membranes to UV light. Nonspecific binding sites of the membrane to the primary antibodies were blocked with 0.3% iBlock solution for 1 h at room temperature. The primary antibodies described below were incubated for 12 h at 4° C, and the secondary antibodies were incubated for 1 h at room temperature. Protein band visualization was obtained by chemiluminescence after ECL reaction (Amersham ECL Prime Western Blotting Detection Reagent) and image capture was performed on ImageQuant 350 gel imager (GE Healthcare, Piscata Way, NJ, USA). The densitometric quantification was performed by ImageJ^® software Version 1.54p 17 February 2025. Membranes were stripped with Restore 2x Western Blot Stripping Buffer (Thermo) for 30 min at 37° C. The densitometric quantification was normalized by the total protein in the pre-stained gel. Total protein is considered a more reliable control than housekeeping proteins [26,27,28].

The following antibodies were used in the study: caspase-1 (diluted 1:500, Imgenex IMG-5028. RRID: AB_316670), IL-1β [diluted 1:500, NovusBio NB600-633, RRID: AB_577977], KCa 2.3 (diluted 1:500, NovusBio NBP3-46424. RRID: AB_3738376), KCa 2.2 (diluted 1:500, NovusBio NBP1-46119. RRID: AB_10009361), ASC [diluted 1:500, Abcam ab175449, RRID:AB_3096354], β-actin (diluted 1:1000, Cell Signaling 5125. RRID: AB_1903890. Total protein in each lane was used as an endogenous control for normalization of all proteins. Membranes were then incubated with the following secondary antibodies: goat anti-mouse IgG H&L (diluted 1:10.000, ab6789, Abcam. RRID: AB_955439) and goat anti-rabbit IgG H&L (diluted 1:10,000, ab6721, Abcam. RRID: AB_955447).

2.10. Statistical Analysis

The declared group size is the number of mice. Statistical analysis was undertaken only for experiments where each group size was at least n = 5 for functional or immunoblots studies, and n = 3 for patch-clamp studies. The Western blot, CC reactivity, and immunohistochemistry results were analyzed by one- or two-way ANOVA and followed by Holm-Šídák post-test according to each analysis. The in vivo results were analyzed by repeated-measures two-way ANOVA and followed by Holm-Šídák post-test. The models’ assumptions were investigated by inspecting Q-Q plots and data were logarithmically transformed when necessary to generate a Gaussian-distributed data set. Relaxation responses were expressed as the percentage change from pre-contraction induced by phenylephrine. Concentration-effect curves were submitted to nonlinear regression analysis using the GraphPad Prism program (GraphPad Prism 9.0; GraphPad Software Inc., San Diego, CA, USA). Relaxant potency and maximal response were expressed as pEC50 (negative logarithm of molar concentration producing 50% of the maximal response) and Emax (maximal effect produced by the agonist), respectively. Statistical analysis of the Emax and pEC50 values was performed using nonlinear regression followed by Student’s t-test or one-way ANOVA. Values of p less than 0.05 were considered statistically significant.

3. Results

3.1. Effect of Endothelin-1 Receptor Inhibition on Erectile Function and NLRP3 Inflammasome Activity in DOCA/Salt Model of Hypertension

In vivo cavernosal nerve stimulation in mice induced a frequency-dependent increase in ICP (Figure 1b,c). When mice were treated with the vehicle (for bosentan), ICP/MAP was reduced in deoxycorticosterone acetate (DOCA)/salt mice at the frequencies from 4 to 20 Hz when compared with unilateral nephrectomized (UNI) mice (Figure 1c). Additionally, DOCA/salt mice had a gradual increment of the blood pressure from days 6 to 9, but then, it was kept sustainedly increased until day 21 (Figure 1d). Bosentan, a non-selective endothelin-1 (ET-1) receptor antagonist, treatment restored the ICP/MAP (Figure 1c) and systolic blood pressure (Figure 1d) in DOCA/salt mice.

Figure 1.

The endothelin receptor antagonist bosentan restores erectile function and inhibits inflammation in DOCA/salt mice. (a) Experimental design. (b) Original tracings showing the intracavernosal pressure (ICP, lower traces) and mean arterial pressure (MAP, upper traces) in response to cavernosal nerve stimulation assessed over a range of frequencies (0.5–20 Hz) in unilateral nephrectomized (UNI) and a DOCA/salt (DOCA) hypertensive mice treated with vehicle or bosentan. (c) Average responses in ICP/MAP and (d) systolic blood pressure of UNI and DOCA hypertensive mice. Immunoblot analysis of (e) caspase-1, (f) IL-1β, and (g) K_Ca 2.3 expression in CC strips of UNI and DOCA hypertensive mice treated with bosentan or vehicle. The arrow indicates when the treatment started (c). Data represent the mean ± SEM values of the groups. * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001. n = 5–11 for functional studies, n = 6 for immunoblots. The comparison of each value was performed by two-way ANOVA followed by the Holm-Šídák post-test. ICP = intracavernosal pressure; MAP = mean arterial pressure. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, and K_Ca 2.3 Western blots are shown in Figures S9 and S11.

In the mouse DOCA/salt model of arterial hypertension, there was a trend of increased caspase-1 activity (measured by the caspase-1/pro-caspase-1 ratio) in CC (Figure 1e). IL-1β activity (obtained by the IL-1β/pro-IL-1β) was increased in the CC from DOCA/salt mice (Figure 1f). On the other hand, K_Ca 2.3 expression was reduced in DOCA/salt mice CC. Additionally, bosentan prevented the caspase-1 activity trend, IL-1β activity increment, and K_Ca 2.3 expression reduction in CC from DOCA/salt mice (Figure 1e–g). Moreover, Bosentan also prevented the reduction in the pro-IL-1β in the CC of DOCA/salt mice (Figure 1g). No significant alterations were observed in the expression of pro-caspase-1, caspase-1, and IL-1β (Figure S2a,b). No alterations were observed in apoptosis speck-like protein containing a card domain (ASC) or K_Ca 2.2 expression (Figures S5 and S6).

DOCA/salt intervention did not modify the contractility to phenylephrine or the relaxation in response to electrical field stimulation of CC (Figure 2b,c). Bosentan did not change phenylephrine-induced contraction or the electrical field stimulation-induced relaxation of CC (Figure 2d,e, Table 1). However, DOCA/salt reduced endothelium-dependent and endothelium-independent relaxations to ACh and SNP, respectively, shifting the concentration-response curves to the right (Figure 2d,e, Table 1). Bosentan treatment of DOCA/salt mice prevented these impairments (Figure 2d,e, Table 1).

Figure 2.

Bosentan restores the impaired endothelium-dependent and -independent relaxations in corpus cavernosum of DOCA/salt mice. (a) Experimental design. (b) Concentration-response curves for phenylephrine, (c) frequency-response curves for electrical-field-stimulation-induced relaxation, and concentration-response curves for (d) ACh and (e) SNP in CC strips of DOCA/salt (DOCA) hypertensive and unilaterally nephrectomized (UNI) mice treated with bosentan or vehicle. The values of the graphics represent mean ± SEM. * p < 0.05 vs. UNI vehicle, ^# p < 0.05 vs. DOCA vehicle. n = 6–8. The comparison of pEC₅₀ and Emax (Table 1) and each value was performed by two-way ANOVA followed by the Holm-Šídák post-test.

Table 1.

Pharmacological inhibition of ET-1 on DOCA/salt-induced impairment of the CC reactivity. Values of Emax and pEC₅₀ for the phenylephrine, ACh, and SNP concentration-effect curves in CC of mice. Curves were performed in CC of unilaterally nephrectomized (UNI) or DOCA/salt-treated mice combined with the treatment with vehicle, bosentan or NS13001.

Pharmacological Inhibition of ET-1 on DOCA/Salt-Induced Impairment of the CC Reactivity.
Drug	UNI	DOCA/salt	UNI bosentan	DOCA/salt bosentan
phenylephrine pEC50 Emax (mN)
	5.89 ± 0.26	5.85 ± 0.30	6.13 ± 0.18	6.04 ± 0.12
	634 ± 68	689.9 ± 87.56	406.1 ± 29.16	487.4 ± 22.95
ACh pEC50
	7.05 ± 0.07	6.55 ± 0.11 *	7.14 ± 0.07 #	7.22 ± 0.06 #
Emax (%)	99 ± 3	88 ± 5	97.30 ± 2.80	95.04 ± 2.12
Sodium nitroprusside pEC50 Emax (%)
	7.18 ± 0.05	6.58 ± 0.05 *	7.59 ± 0.08 #	7.31 ± 0.06 #
	100 ± 5	100 ± 3.70	100 ± 2.22	100 ± 3.42
KCa 2.3 activity on DOCA/salt-induced impairment in the CC reactivity
Drug	UNI NS13001	DOCA/salt NS13001	UNI apamin	DOCA/salt apamin
phenylephrine pEC50
	6.00 ± 0.14	5.98 ± 0.16	5.877 ± 0.12	6.169 ± 0.17
Emax (mN)	473.6 ± 28.05	434.0 ± 28.99	541.7 ± 27.23	513.6 ± 33.95
ACh
pEC50	7.16 ± 0.13 #	7.42 ± 0.08 #	6.828 ± 0.09	6.795 ± 0.11
Emax (%)	100 ± 5	97.33 ± 3.00	90.90 ± 2.36	89.13 ± 2.76
Sodium nitroprusside
pEC50	7.00 ± 0.06 #	7.02 ±0.08 #	6.658 ± 0.10 *	6.569 ± 0.10 *
Emax (%)	100 ± 3	100 ± 3	100 ± 2.21	100 ± 2.40

Values are mean ± SEM (n = 5–11 in each group). * p < 0.05 significantly different from unilateral nephrectomized (UNI). # p < 0.05 significantly different from DOCA/salt (DOCA). The comparison of pEC₅₀ and Emax parameters was performed by two-way ANOVA followed by the Holm-Šídák post-test.

3.2. Effect of NLRP3 Inhibition on Caspase-1 and IL-1β Activity in DOCA/Salt Mice CC

In the mouse DOCA/salt model of arterial hypertension, there was an increased caspase-1 and IL-1β activity in the CC (Figure S1b). On the other hand, K_Ca 2.3 expression was reduced in DOCA/salt mice CC. Additionally, MCC950 (NLRP3 inhibitor) prevented the caspase-1 and IL-1β activity increment, and K_Ca 2.3 expression reduction in CC from DOCA/salt mice (Figure S1a–c). Furthermore, MCC950 also prevented the reduction in the pro-caspase-1 and pro-IL-1β in the CC of DOCA/salt mice (Figure S2c,d). No significant alterations were observed in the expression of caspase-1 and IL-1β (Figure S2c,d). No alterations were observed in ASC or K_Ca 2.2 expression (Figures S5 and S6).

3.3. ET-1 Inhibited the KCa 2.2/2.3 Channels in Endothelial Cells, Impaired the Erectile Function and Activated the NLRP3

The activity of K_Ca 2.2/2.3 channels was measured using whole cell voltage clamps. The K⁺ currents were measured in response to a voltage-step protocol. The total membrane conductance was significantly suppressed in the presence of ET-1 (Figure 3c). The activity of NLRP3 in endothelial cells was evaluated by Western blot for caspase-1 (Figure 3d) and IL-1β activity (Figure 3e), or K_Ca 2.3 expression. These Western blot results suggest that ET-1 administration increased the NLRP3 activity and reduced the KCa 2.3 expression.

Figure 3.

An opener of K_Ca 2.2/2.3 channels restores the background membrane conductance and inhibits inflammation in primary endothelial cells of corpus cavernosum (CC) after endothelin-1 treatment. (a) Experimental design. (b) Representative traces from the (c) current evoked by the voltage-step protocol from −100 to +100 mV in endothelial cells in the presence of vehicle or ET-1 (100 nM) and the effect of NS13001 (100 nM) or apamin (100 nM) administration. The representative traces (upper panel) and the average current-voltage relations (lower panel). Immunoblotting (upper panel) and expression (lower panel) for (d) caspase-1, (e) IL-1β, and (f) K_Ca 2.3 expression in murine CC after the administration of vehicle or ET-1 alone, or combined with NS13001 and apamin. The data is presented as means ± SEM. (c) * p ≤ 0.05 vs. vehicle, ^# p ≤ 0.05 vs. ET-1; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.005, **** p ≤ 0.001. n = 3–6 for patch-clamp studies, n = 6 for immunoblots. Each value was compared by two-way ANOVA followed by the Holm-Šídák post-test. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, and IL-1β Western blots are shown in Figures S18 and S20.

The incubation of CC endothelial cells with NS13001, a K_Ca 2.2/2.3 opener, or MCC950 (NLRP3 inhibitor) significantly reversed the ET-1-induced reduction in the background membrane conductance (Figure 3c) and reduced the NLRP3 activity (Figure 3d,e) and increased K_Ca 2.3 (Figure 3f). Additionally, the incubation with apamin, a K_Ca 2.2/2.3 blocker, did not alter blockage to the total membrane conductance (Figure 3c) and the NLRP3 activity (Figure 3d,e) or K_Ca 2.3 expression (Figure 3f) promoted by ET-1 in endothelial cells from murine CC. No alterations were observed in ASC or K_Ca 2.2 expression (Figures S5 and S6).

Intracavernosal administration of NS13001 rescued ET-1′s reduction in the ICP/MAP responses to submaximal stimuli at 45, 55, and 65 min. Additionally, apamin did not affect ET-1′s impairment of ICP/MAP after its administration (Figure S7b). ET-1 did not change the ICP/MAP responses evoked by maximal stimuli (Figure S7a). Additionally, NS13001 rescued ET-1′s reduction in the ICP/MAP responses to maximal stimuli (Figure S7c).

3.4. Effect of K_Ca 2.2/2.3 Opener on ET1-Induced Erectile Dysfunction and NLRP3 Activity in DOCA/Salt Model of Hypertension

A selective K_Ca 2.2/2.3 opener NS13001 restored erectile function (Figure 4c) and normalized systolic blood pressure (Figure 4d) in DOCA/salt-treated mice. NS13001 also prevented the increment in the caspase-1 and IL-1β activity in the CC from DOCA/salt mice (Figure 4e,f). Additionally, NS13001 prevented the reduction in the K_Ca 2.3 expression (Figure 4g). Moreover, pro-IL-1β expression reduction in the CC from DOCA/salt mice was prevented by NS13001 treatment (Figure S4b). No alterations were observed in ASC or K_Ca 2.2 expression (Figures S5 and S6). NS13001 impaired electric-field-stimulation-induced relaxation at 2 and 4 Hz (Figure 5c). NS13001 prevented the impaired CC relaxation to ACh and SNP promoted by DOCA/salt (Figure 5d,e, Table 1).

Figure 4.

An opener of K_Ca 2 channels, NS13001, restores erectile function and inhibits inflammation in DOCA/salt mice. (a) Experimental design. (b) Original tracings showing the intracavernosal pressure (ICP, lower traces) and mean arterial pressure (MAP, upper traces) in response to cavernosal nerve stimulation assessed over a range of frequencies (0.5–20 Hz) in unilateral nephrectomized (UNI) and DOCA/salt (DOCA) hypertensive mice treated with vehicle or NS13001. (c) Average responses in ICP/MAP and (d) systolic blood pressure of UNI and DOCA mice. Analysis of the (e) caspase-1, (f) IL-1β, (g) and K_Ca 2.3 expression in CC strips from DOCA or UNI mice treated with NS13001 or vehicle. Data represented as mean ± SEM values of the groups. * p < 0.05, ** p ≤ 0.01, *** p ≤ 0.005, **** p ≤ 0.001. n = 5–6 for functional studies, n = 6 for immunoblots. The comparison of each value was performed by two-way ANOVA followed by the Holm-Šídák post-test. ICP = intracavernosal pressure; MAP = mean arterial pressure. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, and K_Ca 2.3 Western blots are shown in Figures S9 and S11.

Figure 5.

NS13001 restores the impaired endothelium-dependent and -independent relaxations in corpus cavernosum of DOCA/salt mice. (a) Experimental design. (b) Concentration-response curves for phenylephrine, (c) frequency-response curves for electrical-field-stimulation-induced relaxation, and concentration-response curves for (d) ACh and (e) and SNP in CC strips of DOCA/salt (DOCA) hypertensive and unilaterally nephrectomized (UNI) mice treated with NS13001 or vehicle. The values of the graphics represented as mean ± SEM. * p < 0.05 vs. UNI vehicle, # p ≤ 0.05 vs. DOCA vehicle. n = 6–8. The comparison of pEC₅₀ and Emax (Table 1) and each value was performed by two-way ANOVA followed by the Holm-Šídák post-test. Figure 5b–e curves share the same UNI and DOCA vehicles as in Figure 2b–e.

3.5. The K_Ca 2.2/2.3 Blocker Apamin Did Not Affect the ET1-Induced Erectile Dysfunction and NLRP3 Activity in DOCA/Salt Model of Hypertension

A selective K_Ca 2.2/2.3 blocker, apamin, impaired erectile function (Figure 6c) and elevated the systolic blood pressure in UNI mice (Figure 6d). Curiously, apamin treatment restored erectile function (Figure 6c) and normalized systolic blood pressure (Figure 6d) in DOCA/salt mice. Apamin also prevented caspase-1 and IL-1β increment in the CC from DOCA/salt mice (Figure 6e,f). Pro-caspase-1 expression was reduced by apamin treatment in the CC of DOCA/salt mice (Figure S4c,d). Furthermore, apamin prevented K_Ca 2.3 expression reduction in the CC of DOCA/salt mice (Figure 6g). Apamin impaired electric-field-stimulation-induced relaxation at the frequencies 8, 16 and 20 Hz (Figure 7b, Table 1). Apamin also prevented the impaired relaxation to ACh and SNP promoted by DOCA/salt treatment (Figure 7c,d, Table 1). No alterations were observed in ASC or K_Ca 2.2 expression (Figures S5 and S6).

Figure 6.

A blocker of K_Ca 2.2/2.3 channels, apamin, inhibits erectile responses in unilaterally nephrectomized control mice and restores responses in DOCA/salt treated mice. (a) Experimental design. (b) Original tracings showing the intracavernosal pressure (ICP, lower traces) and mean arterial pressure (MAP, upper traces) in response to cavernosal nerve stimulation assessed over a range of frequencies (0.5–20 Hz) in unilateral nephrectomized (UNI) and DOCA/salt (DOCA) hypertensive mice treated with vehicle or apamin. (c) Average responses in ICP/MAP and (d) systolic blood pressure of UNI and DOCA hypertensive mice. Analysis of the (e) caspase-1, (f) IL-1β, and (g) K_Ca 2.3 expression in CC strips of DOCA hypertensive or UNI mice treated with apamin or vehicle. Data represented as mean ± SEM values of the groups. * p < 0.05, ** p ≤ 0.01, *** p ≤ 0.005. n = 5–6 for functional studies, n = 6 for immunoblots. Comparisons of each value were performed using a two-way ANOVA followed by the Holm-Šídák post hoc test. ICP = intracavernosal pressure; MAP = mean arterial pressure. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, and K_Ca 2.3 Western blots are shown in Figures S15 and S17.

Figure 7.

Apamin inhibits relaxation in corpus cavernosum (CC) of unilaterally nephrectomized control mice and has no effect on responses in DOCA/salt mice. (a) Experimental design. (b) Concentration-response curves for phenylephrine, (c) frequency-response curves for electrical-field-stimulation-induced relaxation, and concentration-response curves for (d) ACh and (e) and SNP in CC strips of DOCA/salt (DOCA) hypertensive and unilaterally nephrectomized (UNI) mice treated with apamin or vehicle. The values of the graphics represent as mean ± SEM. * p < 0.05. n = 5–6. The comparison of pEC50 and Emax (Table 1) and each value was performed by two-way ANOVA followed by the Holm-Šídák post-test. Figure 7a–d curves share the same UNI and DOCA vehicles as Figure 2a–d. Only UNI apamin and DOCA apamin curves were statistically compared.

4. Discussion

In this study, we found KCa 2.3 channels play a pivotal role in counteracting ET-1-induced NLRP3 activation and subsequent impairment in vascular and erectile function in DOCA/salt hypertensive mice. This study shows that NS13001, a K_Ca 2.3/K_Ca 2.2 channel opener, has therapeutic potential by inhibiting the ET-1 and NLRP3 inflammatory pathways and restoring erectile function. It has been shown that NS13001 has a higher affinity for K_Ca 2.3, and there is no strong evidence for K_Ca 2.2 modulation on endothelial and erectile dysfunction [2,29]. The increase in K_Ca 2.3 expression in hypertensive mice highlights its relevance in hypertension. Furthermore, as the ET-1 receptor antagonist, bosentan, normalized blood pressure and erectile function in DOCA/salt mice, it underscores the central role of ET-1 in these dysfunctions, and we suggest that it is modulated through the potassium channels.

In the previous study, we showed that NLRP3 modulates erectile function in mice [4]. In addition, it was shown that ET-1-induced erectile dysfunction, and pro-inflammatory effect depends on NLRP3 activation [24]. These findings offer valuable insights into the intricate interplay among ET-1, K_Ca 2.2/2.3 channels, and NLRP3 inflammasome, suggesting potential targets for novel therapeutic interventions for inflammatory-related diseases and the restoration of erectile function.

In accordance with our study, several previous studies reported that DOCA/salt treatment leads to hypertension in rodents [6,7,8]. We found that the DOCA/salt mouse model presented a gradual increase in blood pressure, impairment in erectile function, and reduced relaxation to ACh and SNP, i.e., endothelium-dependent and endothelium-independent relaxations, respectively [1,21]. The detrimental effect of DOCA/salt hypertension in rodents on erectile dysfunction was reported previously [21,30]. However, the mechanism behind it was not elucidated. We found in this study that it is associated with ET-1 signaling, leading to changes in the expression of K_Ca 2.3 and the NLRP3 inflammasome.

ET-1 treatment leads to endothelial dysfunction, mainly by reducing the function of various populations of potassium channels, such as inward rectifier (Kir) [30], sensitive ATP (KATP) [31,32], voltage-gated (Kv) [33], and calcium-activated (KCa) [15] potassium channels. Moreover, it was already shown that ET-1 exposure releases pro-inflammatory cytokines, like TNF-α [31] and e IL-1β, in monocytes [32] and smooth muscle cells [33]. Accordingly, in this study, treatment with bosentan, an ET-1 type A (ET_A) and B (ET_B) receptor antagonist [34], or MCC950, an NLRP3 inhibitor, restored the K_Ca 2.3 abundance and reduced NLRP3 activity in DOCA/salt mice, suggesting that ET-1 activity in the CC of DOCA/salt mice is mediated via NLRP3 activation [4,24]. Furthermore, treatment with bosentan restored blood pressure, erectile function, and ACh- and SNP-induced relaxation, suggesting that ET-1 signaling contributes to these abnormalities in the DOCA/salt model of hypertension. This is in line with previous reports that administration of ET-1 antagonists reduces the elevation of blood pressure, reverses cardiac hypertrophy and arterial remodeling [16], left ventricular fibrosis [17,18], inflammation, and renal hypertrophy [18].

Accordingly, ET-1 reduces the total membrane conductance in endothelial cells, and our interventions with the K_Ca 2.2/2.3 activator and inhibitor, or NLRP3 inhibitor suggest that this effect is primarily because of the impairment to K_Ca 2.2/2.3 function and NLRP3 inhibition. Notably, the K_Ca 2.3 is expressed explicitly in endothelial but not smooth muscle cells of corpus cavernosum [2]. The K_Ca 2.2 is also expressed in the mouse corpus cavernosum, but the role and location of the expression is less known [35]. It has previously been shown that ET-1 leads to endothelial dysfunction in the pulmonary artery, but mainly, this effect was mediated via reduction in the intermediate-conductance calcium-activated potassium channels, i.e., K_Ca 3.1 [15]. ET-1 was also shown to inhibit the K_Ca1.1 in cultured smooth muscle cells from porcine coronary artery [36]. Therefore, this is the first time the inhibitory effect of ET-1 on K_Ca 2.3/2.2 activity has been reported in endothelial cells.

Administration of the K_Ca 2.2/2.3 modulator, NS13001, or MCC950, restored the K_Ca 2.2/2.3 current in endothelial cells incubated with ET-1. Interestingly, it also reduced the NLRP3 activity and restored both endothelium-dependent and endothelium-independent relaxations impaired by exposure to ET-1. K_Ca 2.3 channels were suggested to be involved in endothelium-dependent vasodilatation in human and rat intracavernous penile arteries [12,13]. K_Ca 2.3 activation regulates L-arginine uptake through the y+ transporter system and increased NO release [5], which will counteract the effect of ET-1.

The treatment with NS13001 also reduced caspase-1 and pro-IL-β activity and restored K_Ca 2.3 abundance in DOCA/salt mice CC. It can also be mediated via an anti-inflammatory effect of the K_Ca 2.2/2.3 channels, mainly, because it is known to inhibit the release of proinflammatory cytokines such as IL-6, TNF-α, and the migration of immune system cells [37]. Interestingly, the treatment with apamin reduced K_Ca 2.3 expression in the CC of unilaterally nephrectomized mice with no effect in DOCA/salt hypertensive mice, possibly because it is already downregulated. Following our suggestion about the anti-inflammatory effect of the K_Ca 2.3, apamin administration increased caspase-1 and IL-β activity in DOCA/salt mice CC but not in UNI. Here, it is possible to suggest that the reduction in the K_Ca 2.3 expression correlates with the impairment of its function, once the apamin treatment reduces the K_Ca 2.3 expression. Additionally, apamin has a pro-inflammatory action [38]. Curiously, apamin lowered blood pressure and increased erectile function in DOCA/salt mice. Apamin has been previously shown to protect against atherosclerosis by reducing lesion burden, lipid levels, inflammation, and fibrotic markers [39]. Furthermore, KCa 2.3 blockade by apamin prevented mineralocorticoid-induced thickening of the vascular wall in the human retina [40]. Suggesting that the reduction in the vascular wall thickening, fibrotic, and inflammatory markers by apamin are involved with the reduction in the systolic pressure. Moreover, modulating apamin-sensitive SK (small-conductance Ca²⁺-activated K⁺) current, which influences action potential duration and arrhythmia in failing ventricles, selectively reduces nNOS after-hyperpolarization, and its effects on SK channels can be modified by nNOS inhibition [41,42,43]. Indeed, we observed that apamin increased the CC response to non-adrenergic and non-cholinergic stimulation, suggesting that apamin may be reducing the after-hyperpolarization of the cavernosal nerve.

Importantly, the MCC950, a specific NLRP3 inhibitor, restores a mix of K_Ca 2.3 and other ionic currents. In fact, several Ca²⁺-channels [transient related canonic (TRC) or potential (TRP) channels] or H⁺-channels could also lead to K⁺ efflux from the cell, and this mechanism could be responsible for NLRP3 activation [19]. Then, the MCC950 mechanism of NLRP3 inhibition could be related to the modulation of these channels. Additionally, an administration of MCC950 prevented the erectile dysfunction induced by ET-1. Previous data from our lab had already shown that the NLRP3 genetic deletion or pharmacological inhibition prevents the impairment of endothelium-dependent relaxation evoked by ET-1 in mice CC [24]. Indeed, ET-1, via ET receptor A or B increase cytosolic Ca²⁺ concentration in vascular smooth muscle cells [44], liver cells and cardiomyocytes [45,46].

Limitations

In the present study we investigated whether activating K_Ca 2.2/2.3 channels reverses erectile dysfunction and ET-1-induced NLRP3 activation in hypertensive DOCA/salt mice. Therefore, the findings in the study apply to mouse male sexual function, and further studies on human erectile tissue will be required to clarify whether the same mechanism plays a role in men with erectile dysfunction, and other models will have to be investigated to extend whether these mechanisms also play a role in the female genitalia. The ICP/MAP ratio was used to measure the erectile function under isoflurane anesthesia. Isoflurane is known to depress the cardiovascular system not only by direct action but also by suppression of the sympathetic nervous system [47,48]. NS13001 has been shown to bind to and to activate K_Ca 2.2 and K_Ca 2.3 channels [2,49]. There is limited information regarding the potential off-target effects of the molecule and whether activation of K_Ca 2.2 and K_Ca 2.3 channels may influence cardiac rhythm in connection with atrial fibrillation, where blockers of these channels were recently found to have a beneficial clinical effect [41,50,51].

5. Conclusions

In conclusion, our study shows the role of K_Ca 2.3 channels in ET-1-induced NLRP3 activation and subsequent impairment in vascular and erectile function in DOCA/salt hypertensive mice. The novel findings highlight the therapeutic potential of the K_Ca 2.2/2.3 channel modulator, NS13001, in inhibiting the ET-1 and NLRP3 inflammatory pathways, ultimately leading to the restoration of erectile function. The observed compensatory increase in the K_Ca 2.3 expression in hypertensive mice underscores its significance in hypertension. Furthermore, the efficacy of the ET-1 receptor antagonist, bosentan, in attenuating these effects emphasizes the central role of ET-1 in inducing vascular and erectile dysfunction through the modulation of potassium channels. Our results provide valuable insights into the complex interplay between ET-1, K_Ca 2.2/2.3 channels, and NLRP3 inflammatory-related diseases, paving the way for potential therapeutic interventions targeting these pathways to ameliorate inflammatory-related diseases and restore erectile function.

Abbreviations

The following abbreviations are used in this manuscript:

ASC	Apoptosis Speck-like protein containing a CARD domain
Ca2+	Calcium
K+	Potassium
KCa 2.3	Ca2+-activated K+ channels type 2.3
ET-1	Endothelin-1
ICP	Intracavernous pressure
CC	Corpus cavernosum
IL	Interleukin
SKCa	Small conductance Ca2+-activated K+ channels
IKCa	Intermediate conductance Ca2+-activated K+ channels
BKCa	Large conductance Ca2+-activated K+ channels
ED	Erectile dysfunction
NO	Nitric oxide
eNOS	Endothelial NO synthase
TNF-α	Tumor necrosis factor-alpha
Kir	Inward-rectifying K+ channels
KATP	ATP-sensitive K+ channels
Kv	Voltage-gated K+ channels
DOCA	Deoxycorticosterone acetate
UNI	Unilaterally nephrectomized
SBP	Systolic blood pressure
ICAM2	Intracellular adhesion molecule 2
MAP	Mean arterial pressure
ACh	Acetylcholine
SNP	Sodium nitroprusside

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/biom16030432/s1, Figure S1. NLRP3 inhibition prevents inflammation in DOCA/salt mice. (a) Experimental design. Immunoblot analysis of (b) caspase-1, (c) IL-1β, and (d) KCa2.3 expression in CC strips of UNI and DOCA hypertensive mice treated with MCC950 or vehicle. The arrow indicates when the treatment started (c). Data represent the mean ± SEM values of the groups. * p < 0.05. n = 6. The comparison of each value was performed by two-way ANOVA followed by the Holm-Šídák post-test. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, and KCa2.3 are shown in Figures S12 and S14; Figure S2. Analysis of the (a and c) pro-caspase-1and caspase-1, (b and d) pro-IL-1β and IL-1β expression in CC strips of DOCA/salt hypertensive (DOCA) or unilaterally nephrectomized (UNI) rats treated with vehicle, (a and b) bosentan or (c and d) MCC950. Data represent the mean ± SEM values of the groups. * p < 0.05. n = 6. Each value was compared by two-way ANOVA followed by The Holm-Šídák post-test. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, and KCa2.3 are shown in Figures S9, S11, S12 and S14; Figure S3. Analysis of the (a) pro-caspase-1and caspase-1, (b) pro-IL-1β and IL-1β expression in CC strips of healthy mice treated with vehicle, or ET-1 in the presence or absence of NS13001, apamin, and MCC950. Data represent the mean ± SEM values of the groups. * p < 0.05. n = 6. Each value was compared by two-way ANOVA followed by The Holm-Šídák post-test. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, and KCa2.3 are shown in Figures S18 and S20; Figure S4. Analysis of the (a and c) pro-caspase-1and caspase-1, (b and d) pro-IL-1β and IL-1β expression in CC strips of DOCA/salt hypertensive (DOCA) or unilaterally nephrectomized (UNI) mice treated with vehicle, (a and b) NS13001 or (c and d) apamin. Data represent the mean ± SEM values of the groups. * p < 0.05. n = 6. Each value was compared by two-way ANOVA followed by The Holm-Šídák post-test. The entire membranes for pro-caspase-1, caspase-1, pro-IL-1β, IL-1β, and KCa2.3 are shown in Figures S12, S14, S15 and S17; Figure S5. Analysis of the ASC in CC strips of DOCA/salt hypertensive (DOCA) or unilaterally nephrectomized (UNI) rats treated with vehicle, (a) bosentan, (b) MCC950, (d) NS13001, (e) apamin. (c) ASC expression in CC strips of healthy mice treated with vehicle, or ET-1 in the presence or absence of NS13001, apamin, and MCC950. Data represent the mean ± SEM values of the groups. * p < 0.05. n = 6. Each value was compared by two-way ANOVA followed by The Holm-Šídák post-test. The entire membranes for ASC are shown in Figures S10, S13, S16 and S19; Figure S6. Analysis of the KCa2.2 in CC strips of DOCA/salt hypertensive (DOCA) or unilaterally nephrectomized (UNI) rats treated with vehicle, (a) bosentan, (b) MCC950, (d) NS13001, (e) apamin. (c) KCa2.2 expression in CC strips of healthy mice treated with vehicle, or ET-1 in the presence or absence of NS13001, apamin, and MCC950. Data represent the mean ± SEM values of the groups. * p < 0.05. n = 6. Each value was compared by two-way ANOVA followed by The Holm-Šídák post-test. The entire membranes for ASC are shown in Figures S10, S13, S16 and S19; Figure S7. Effect of KCa2.3 opener or inhibitor on ICP/MAP ratio. (a) Original tracings showing the intracavernosal pressure (ICP, lower traces) and mean arterial pressure (MAP, upper traces) in response to cavernosal nerve stimulation assessed. The graphics depict the ICP/MAP ratio in response to cavernosal nerve stimulation: (b) submaximal (2, 4 or 8 Hz) at 3, 10, 20 and 30 min and (c) maximal (16 Hz) at 25 min after the injection of the vehicle followed by a new vehicle administration. Submaximal stimulation at 35, 38, 45, 55, and 65 min and maximal at 60 min, ET‐1 followed by vehicle, NS13001 or apamin followed by ET‐1 or vehicle. Data represent mean ± SEM of ICP/MAP values. Representative tracings showing changes in intracavernosal pressure and blood pressure in response to electrical stimulation of the cavernosal nerve. * p < 0.05. n = 5–9. Each frequency value for the ICP/MAP was performed by repeated‐measures two‐way ANOVA followed by Holm- Šídák post‐test. ICP = intracavernosal pressure; MAP = mean arterial pressure. The continuous arrow represents the first administration at 0 min and the dashed arrow represents the second administration at 35 min; Figure S8. Concentration-response curves to (a and c)acetylcholine, and sodium (b and d) nitroprusside in CC strips incubated with (a and b) NS13001 or (c and d) apamin of healthy mice. * p < 0.05. n = 5–6. The comparison of pEC50 and Emax (Table 1) and each value was performed by two-way ANOVA followed by Holm-Šídák post-test; Figure S9. The membranes exposed to cheminoluminescence (a, c, d) and epiluminescence (b, d, f) to develop the immunoblotting for (a, b) pro-caspase-1, caspase-1, (c, d) pro-IL-1β, IL-1β, (e, f) and KCa 2.3; Figure S10. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) KCa 2.2 and (c, d) ASC; Figure S11. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) β-actin; Figure S12. The membranes exposed to cheminoluminescence (a, c, d) and epiluminescence (b, d, f) to develop the immunoblotting for (a, b) pro-caspase-1, caspase-1, (c, d) pro-IL-1β, IL-1β, (e, f) and KCa 2.3; Figure S13. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) KCa 2.2 and (c, d) ASC; Figure S14. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) β-actin; Figure S15. The membranes exposed to cheminoluminescence (a, c, d) and epiluminescence (b, d, f) to develop the immunoblotting for (a, b) pro-caspase-1, caspase-1, (c, d) pro-IL-1β, IL-1β, (e, f) and KCa 2.3; Figure S16. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) KCa 2.2 and (c, d) ASC; Figure S17. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) β-actin; Figure S18. The membranes exposed to cheminoluminescence (a, c, d) and epiluminescence (b, d, f) to develop the immunoblotting for (a, b) pro-caspase-1, caspase-1, (c, d) pro-IL-1β, IL-1β, (e, f) and KCa 2.3; Figure S19. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) KCa 2.2 and (c, d) ASC; Figure S20. The membranes exposed to cheminoluminescence (a and c) and epiluminescence (b and d) to develop the immunoblotting for (a, b) β-actin.

Author Contributions

Conceptualization, R.S.F., S.G.C.-S., R.T., F.S.C. and U.S.; Methodology, R.S.F., E.P., V.V.M., R.T., F.S.C. and U.S.; Software, U.S.; Validation, R.S.F., S.G.C.-S., V.V.M., F.S.C. and U.S.; Formal analysis, R.S.F., S.G.C.-S., E.P., V.V.M., F.S.C. and U.S.; Investigation, R.S.F., S.G.C.-S., V.V.M., F.S.C. and U.S.; Resources, R.S.F., S.G.C.-S., R.T. and U.S.; Data curation, R.S.F., S.G.C.-S., V.V.M. and U.S.; Writing—original draft, R.S.F., F.S.C. and U.S.; Writing—review & editing, R.S.F., S.G.C.-S., E.P., V.V.M., R.T., F.S.C. and U.S.; Visualization, R.S.F., E.P. and F.S.C.; Supervision, S.G.C.-S., V.V.M., R.T., F.S.C. and U.S.; Project administration, R.S.F.; Funding acquisition, R.S.F., R.T., F.S.C. and U.S. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

All experimental protocols adhered to the ARRIVE guidelines, followed Danish legislation of animal use for scientific procedures as described in the ‘Animal Testing Act’ (Consolidation Act No. 726 of 9 September 1993 as amended by Act No. 1081 of 20 December 1995) and were approved by the Danish Animal Experiments Inspectorate (permission 2019-15-0201-00009; approved on 24 June 2019).

Informed Consent Statement

Not applicable.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.

Conflicts of Interest

The authors declare no conflict of interest.

Funding Statement

This research was funded by PHAB Level 3, AHA Postdoctoral fellowship (24POST1243617), the Sao Paulo Research Foundation (FAPESP, 2016/11988-5; 2016/07641-0; 2018/05638-7; 2019/19749-8); Novo Nordisk Foundation (NFF130C0007739; NFF60C0023284) and Wilhelm Pedersen and Wife’s memorial grant.